AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.
The Anglo-Swedish pharma giant AZN, +2.26% said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.
Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.
Write to Kyle Morris at kyle.morris@dowjones.com